DAFTAR PUSTAKA

1. Sayutti N, Abu MA, Ahmad MF. PCOS and Role of Cumulus Gene Expression in Assessing Oocytes Quality. *Fronties in Endocrinology*. May 2022;13:1-13.
2. Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 International Evidence-Based Guideline For the Assessment and Management of Polycystic Ovary Syndrome. *European Journal of Endocrinology*. 2023;189(2):G43-G64.
3. International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. *American Society for Reproductive Medicine*. 2018:1-201.
4. Audrey UK, Decanter C, Grysole C, Keller L, Behal H, Silva M, et al. Polycystic Ovary Syndrome Phenotype does not have Impact on Oocyte Morphology. *Reproductive Biology and Endocrinology*. 2022;20(7):1-13.
5. Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, et al. Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics. *Journal of Clinical Medicine*. 2023;12(1454):1-24.
6. Bulsara J, Patel P, Soni A, Acharya S. A review : Brief Insight into Polycystic Ovarian Syndrome. *Endocrine and Metabolic Science*. 2021:100085;1-7.
7. Ismayilova M, Yaya S. "I'm Usually Being My Own Doctor": Women's Experiences of Managing Polycystic Ovary Syndrome in Canada. *International Health*. 2023;15:56-66.
8. Deswal R, Narwal V, Dang A, Pundir CS. The Prevalence of Polycystic Ovary Syndrome: A Brief Systematic Review. *Journal Human Reproduction Science*. 2020;13(4):261-271.
9. Ding T, Hardiman PJ, Petersen I, Wang FF, Qu F. The Prevalence of Polycystic Ovary Syndrome in Reproductive Aged Woman of Different Ethnicity: A Systematic Review and Meta-Analysis. *Oncotarget*. 2017;8(56):96351-96358.

10. Engmann L, Jin S, Sun F, Legro RS, Polotsky AJ, Hansen KR, et al. Racial and Ethnic Differences in the Polycystic Ovary Syndrome Metabolic Phenotype. *American Journal of Obstetrics and Gynecology*. 2017;216(5):1-13.

11. Ganie MA, Vasudevan V, Wani IA, Baba MS, Arif T, Rashid A. Epidemiology, Pathogenesis, Genetics, & Management of Polycystic Ovary Syndrome in India. *Indian Journal of Medical Research*. 2019;150(4):333-344.

12. Mareta R, Amran R, Larasati V. Hubungan PCOS dengan Infertilitas di Praktik Swasta Dokter Obstetri Ginekologi Palembang. *Majalah Kedokteran Sriwijaya*. 2018;50(2):85-91.

13. Putra DD, Sari DR, Annas JY, Santoso B. Characteristics of Polycystic Ovary Syndrome (PCOS) at Soetomo General Hospital Surabaya. *Health Notions*. 2019;3(11):453-458.

14. Wahyuni M, Decroli E, Lasmini PS. Hubungan Resistensi Insulin dengan Gambaran Klinis Sindrom Ovarium Polikistik. *Jurnal Kesehatan Andalas*. 2105;4(3):1-9.

15. Pena AS, et al. Adolescent Polycystic Ovary Syndrome According to the International Evidence-based Guideline. *BMC Medicine*. 2020;18(72):1-16.

16. Kamboj MK, Bonny AE. Polycistic Ovary Syndrome in Adolescence: Diagnosis and Therapeutic Strategies. *Translational Pediatrics*. 2017;6(4):248-255.

17. Fahs D, Salloum D, Nasrallah M, Ghazeeri G. Polycystic Ovary Syndrome: Pathophysiology and Controversies in Diagnosis. *Diagnostics*. 2023:13(1559);1-13.

18. Adashi EY, Cibula D, Peterson M, Azziz R. The Polycystic Ovary Syndrome: the First 150 Years of Study. *American Society for Reproductive Medicine*. 2023;4(1):1-13.

19. Mohammadi M. Oxidative Stress and Polycystic Ovary Syndrome : A Brief Review. *International Journal Previous Medicine*. 2019;10(86):1-7.

20. Uckan K, Demir H, Turan K, Sarikaya E, Demir C. Role of Oxidative Stress in Obese and Non Obese PCOS patients. *International Journal of Clinical Practice*. 2022;2022:1-9.
21. Sandhu JK, Waqar A, Jain A, Joseph C, Srivastava K, Ochuba O, et al. Oxidative Stress in Polycystic Ovarian Syndrome and the Effect of Antioxidant N-Acetylcysteine on Ovulation and Pregnancy Rate. *Journal of Medical Science*. 2021;13(9):e17887.
22. Greff D, Juhasz AE, Vansca S, Varadi A, Sipos Z, Szinte J, et al. Inositol in an Effective and Safe Treatment in Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Reproductive Biology and Endocrinology*. 2023;21(10):1-12.
23. Unfer V, Nestler JE, Kamenov ZA, Prapas N, Facchinetti F. Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials. *International Journal of Endocrinology*. 2016;2016:1-13.
24. Kalra B, Kalra S, Sharma JB. Inositols and PCOS. *Metabolic Endocrinology Journal India*. 2016;20(5):720-724.
25. Kamenov Z, Gateva A. Inositols in PCOS. *Molecules*. 2020;25(23):5566.
26. Malik N, Dubey N. Role of Oral Inositol Supplementation in Women with Polycystic Ovarian Syndrome. *International Journal of Reproduction, Contraception, Obstetrics, and Gynecology*. 2021;10(12):4493-4498.
27. Dewi NLPR, Pendekatan Terapi PCOS. *CDK-290*.2020;47(9):703-705.
28. Konsensus Tatalaksana Sindrom Ovarium Polikistik. HIFERI. 2016.
29. Barber TM, Franks S. Obesity and Polycystic Ovary Syndrome. *Clinical Endocrinology*. 2021;95:531-541.
30. Loos ADD, Hund M, Buck K, Meun C, Silman J, Laven JSE. Antimullerian Hormone to Determine Polycystic Ovarian Morphology. *Fertility and Sterility*. 2021;116(4):1149-1157.

31. Bai X, Zheng L, Li D, Xu Y. Research Progress of Endometrial Receptivity in Patients with Polycystic Ovary Syndrome: a Systematic Review. *Reproductive Biology and Endocrinology*. 2021;19(122):1-18.

32. Barrea L, Toral EF, Verde L, Ceriani F, Cucalon G, Velasquez EG, et al. PCOS and Nutritional Approaches: Differences between Lean and Obese Phenotype. *Metabolism Open Elsevier*. 2021;12(100123):1-8.

33. Haas CL, Varbo A, Laursen PN, Schnecke V, Balen AH. Association Between Body Mass Index, Weight Loss and the Chance of Pregnancy in Women with Polycystic Ovary Syndrome and Overweight or Obesity: a Retrospective Cohort Study in the UK. *Human Reproduction*. 2023;38(3):471-481.

34. Liu Y, Li J, Yan Z, Liu D, Ma J, Tong N. Improvement if Insulin Sensitivity Increases Pregnancy Rate in Infertile PCOS Women: a Systematic Review. *Frontiers in Endocrinology*. 2021;12(657889):1-10.

35. Khomani MB, Teede HJ, Joham AE, Moran LJ, Piltonen TT, Boyle JA. Clinical Management of Pregnancy in Women with Polycystic Ovary Syndrome: An Expert Opinion. *Clinical Endocrinology.* 2022;97:227-236.

36. Wattar BHA, Fisher M, Bevington L, Talaulikar V, Davies M, Conway G, Yasmin E. Clinical Practice Guidelines on the Diagnosis and Management of Polycystic Ovary Syndrome: A Systematic Review and Quality Assessment Study. *The Journal of Clinical Endocrinology and Metabolism*. 2021;106(8):2436-2446.

37. Zolton JR, Torrealday S. In Vitro Fertilization for Polycystic Ovarian Syndrome. *Clinical Obstetrics and Gynecology*. 2021;64(1):39-47.

38. Merviel P, James P, Bouée S, Le Guillou M, Rince C, Nachtergaele C, Kerlan V. Impact of *Myo-inositol* Treatment in Women with Polycystic Ovary Syndrome in Assisted Reproductive Technologies. *Reproductive health*. 2021 Dec;18:1-8.

39. Dinicolantonio JJ, O'Keefe JH. *Myo-inositol* for Insulin Resistance, Metabolic Syndrome, Polycystic Ovary Syndrome, and Gestasional Diabetes. *BMJ*. 2022;9(1):e001989.

40. Lagana AS, Garzon S, Casarin J, Frachi M, Ghazzi F. Inositol in PCOS: Restoring Fertility Through a Pathophysiology-based Approach. *Trends in Endocrinology & Metabolism*. 2018;29:768-780.

41. Chirania K, Misra S, Behera S. A Randomised Clinical Trial Comparing *Myo-inositol* and Metformin in PCOS. *International Journal of Reproduction, Contraception, Obstetrics, and Gynecology*. 2017;6(5):1814–1820.

42. Dinicola S, Unfer V, Facchinetti F, Soulage CO, Greene ND, Bizzarri M, et al. Inositols: From Established Knowledge to Novel Approaches. *International Journal of Molecular Sciences*. 2021;22(19):10575.

43. Zeng L, Yang K. Effectiveness of *Myo-inositol* for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis. *Endocrine*. 2018;59(1):30–38.

44. Pundir J, Psaroudakis D, Savnur P, Bhid P, Sabatini L, Teede H, et al. Inositol Treatment of Anovulation in Women with Polycystic Ovary Syndrome: A Meta-analysis of Randomised Trials. *BJOG*. 2018;125(3):299–308.

45. Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera M. A Combined Therapy with *Myo-inositol* and *D-chiro-inositol* Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women. *International Journal Endocrinology*. 2016;2016:3204083.

46. Kutenaei MA, Teshnizi SH, Ghaemmaghami P, Eini F, Roozbeh N. The Effects of *Myo-inositol* vs Metformin on the Ovarian Function in the Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis. *European Review for Medical and Pharmacological Sciences*. 2021;25(7):3105–3115.

47. Rena G, Hardie DG, Pearson ER. The Mechanisms of Action of Metformin. *Diabetologia*. 2017;60(9):1577–1585.

48. Macut D, Macut JB, Rahelic D, Doknic M. Insulin and the Polycystic Ovary Syndrome. *Diabetes Research and Clinical Practice*. 2017;130:163–170

49. Lebovitz HE. Thiazolidinediones: the Forgotten Diabetes Medications. *Current Diabetes Reports*. 2019;19(12):151.

50. Stankovic VS, Pejicic SP, Stankovic S, Prtina A, Malesevic G, Macut JB, et al. The Effect of Metformin and *Myo-inositol* on Metabolic Outcomes in Women with Polycystic Ovary Syndrome: Role of Body Mass and Adiponectin in a Randomized Controlled Trial. *Journal of Endocrinological Investigation*. 2022;45(3):583–595.

51. Rajasekaran K, Malhotra N, Mahey R, Khadgawat R, Kalaivani M. *Myo-inositol* Versus Metformin Pretreatment in GnRH-antagonist Cycle for Women with PCOS undergoing IVF: A Double-blinded Randomized Controlled Study. *Gynecology Endocrinology*. 2022;38(2):140–147.

52. Shokrpour M, Foroozanfard F, Ebrahimi FA, Vahedpoor Z, Aghadavod E, Ghaderi A, et al. Comparison of *Myo-inositol* and Metformin on Glycemic Control, Lipid Profiles, and Gene Expression Related to Insulin and Lipid Metabolism in Women with Polycystic Ovary Syndrome: A Randomized Controlled Clinical Trial. *Gynecological Endocrinology*. 2019;35(5):406–411.

53. Nehra J, Kaushal J, Singhal SR, Ghalaut VS. A Comparative Study of Myo inositol Versus Metformin on Biochemical Profile in Polycystic Ovarian Syndrome in Women. *International Journal of Pharmaceutical Sciences and Research*. 2017;8(4):1664–1670.

54. Facchinetti F, Orru B, Grandi G, Unfer V. Short-Term Effects of Metformin and *Myo-inositol* in Women with Polycystic Ovarian Syndrome (PCOS): A Meta-analysis of Randomized Clinical Trials. *Gynecological Endocrinology*. 2019;35(3):198–206.

55. Sortino MA, Salomone S, Carruba MO, Drago F. Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols. *Frontiers*. 2017;8:1-13.

56. Bargues CM, Escriva C, Dromant M, Barras C, Vina J. Lipid Peroxidation as Measured by Chromatographic Determination of Malondialdehyde Human Plasma Reference Values in Health and Disease. *Archives of Biochemistry and Biophysics*. 2021;108941:1-7.

57. Mulianto N. Malondialdehide sebagai Penanda Stress Oksidatif pada Berbagai Penyakit Kulit. *Cermin Dunia Kedokteran*. 2020;47(1):39-44.

58. Salekeen R, Haider AN, Akhter F, Billah MM, Islam ME, Islam KMD. Lipid Oxidation in Pathophysiology of Atherosclerosis : Current Understanding and Therapeutic Strategies. *International Journal of Cardiology Cardiovascular Risk and Prevention*. 2022;200143:1-16.

59. Jove M, Martorell NM, Pradas I, Gari MM, Ayala V, Pamplona R. The Advanced Lipoxidation End-Product Malondialdehyde-Lysine in Aging and Longevity. *Antioxidants*. 2020;9(1132):1-20.

60. Achi ZI, Perez PJ, Gonzalez PA, Mejias RL, Gonzalez CM, Gonzalez-Gay MA, et al. Malondialdehyde Serum Levels in Patients with Systemic Sclerosis Relate to Dyslipidemia and Low Ventricular Ejection Fraction. *Antioxidants*. 2023;12(1668):1-18.

61. Zhao H, Zhang J, Cheng X, Nie X, He B. Insulin Resistance in Polycistic Ovary Syndrome Across Various Tissues: an Updated Review of Pathogenesis, Evaluation, and Treatment. *Journal of Ovarian Research*. 2023;16(9):1-17.

62. Chavez GN, Jaworsky K, Basu A. The Effects of Plant-Derived Phytochemical Compounds and Phytochemical-Rich Diets on Females with Polycistic Ovarian Syndrome: a Scoping Review of Clinical Trials. *International Journal of Enviromental Research and Public Health*. 2023;20(6534)1-17.

63. Mansour A, Hosseini S, Larijani B, Tehrani MRM. Nutrients as Novel Therapeutic Approaches for Metabolic Disturbances in Polycystic Ovary Syndrome. *Experimental and Clinical Sciences Journal*. 2016;15:551-564.